Results 161 to 170 of about 26,612 (257)

A case report of dipeptidyl peptidase 4 inhibitor-related kidney disease combined with renal cancer. [PDF]

Front Nephrol
Kurihara S, Sawa N, Sumida K, Ikuma D, Oba Y, Mizuno H, Sekine A, Yamanouchi M, Hasegawa E, Suwabe T, Urakami S, Kono K, Kinowaki K, Ohashi K, Yamaguchi Y, Ubara Y.   +15 more
europepmc   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Journal of Diabetes Investigation, EarlyView.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami   +4 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitor linagliptin improves fibrosis, apoptosis, and cardiac function in a large animal model of chronic myocardial ischemia. [PDF]

J Pharmacol Exp Ther
Harris DD, Stone C, Broadwin M, Kanuparthy M, Sabe SA, Nho JW, Hamze J, Abid MR, Sellke FW.   +8 more
europepmc   +1 more source

Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy

Journal of Diabetes Investigation, EarlyView.
Older age, atrial fibrillation, loop diuretic use, and higher eGFR variability predicted early eGFR dip. Continued SGLT2 inhibitor therapy preserved long‐term kidney function, although closer monitoring is warranted in patients receiving loop diuretics. ABSTRACT Aim To assess the prevalence, risk factors, estimated glomerular filtration rate trajectory,
Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee   +7 more
wiley   +1 more source

Association between the body mass index and risk of cardiovascular events in sodium-glucose cotransporter 2 inhibitor users compared with dipeptidyl-peptidase 4 inhibitor users: A nationwide cohort study in Korea. [PDF]

Diabetes Obes Metab
Ko HY, Jung K, Cho Y, Bea S, Bae JH, Cho YM, Rhee SY, Shin JY.   +7 more
europepmc   +1 more source

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source

Rurality is associated with lower likelihood of dipeptidyl peptidase 4 inhibitor use for treatment intensification. [PDF]

Explor Res Clin Soc Pharm
Nagy DK, Bresee LC, Eurich DT, Simpson SH.   +3 more
europepmc   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source

A case of immunoglobulin G4-related kidney disease manifesting after dipeptidyl peptidase-4 inhibitor treatment. [PDF]

CEN Case Rep
Ubara Y, Takeuchi T, Hasegawa E, Sekine A, Inoue N, Tanaka K, Mizuno H, Oba Y, Yamanouchi M, Suwabe T, Kono K, Kinowaki K, Ohashi K, Yamaguchi Y, Sawa N, Wada T.   +15 more
europepmc   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source